ArticleACS sensors2025
Signal Enhancement in Immunoassays via Coupling to Catalytic Nanoparticles.
Article in ACS sensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Rational Optimization Approach for the Development of a Multiplexed Lateral Flow Immunoassay: Detection of Nonepithelial Ovarian Cancer Markers in Human Serum.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Magnetically Retrievable Platinum Nanoreporters for Efficient Lateral Flow Immunoassay in Complex Bio-Samples.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Evaluation of Malaria Parasite Transmission Competency Using a Nanozyme-Based Immunodiagnostic Targeting Female Gamete Antigen Release.ACS nano · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Early diagnosis is vital for effective disease management, selection of appropriate treatment regimes, and surveillance and control of disease transmission. There is a growing need for point-of-need diagnostic platforms, such as lateral flow immunoassays (LFIAs), to reduce healthcare burdens, particularly in low-resource settings. However, LFIAs often suffer from inadequate sensitivity and exhibit limited dynamic ranges, leading to late-stage diagnosis or misdiagnosis. Here, we present a signal enhancement platform for use in both plate- and paper-based immunoassays, based on the formation of a coupled nanoparticle network. We demonstrate the coupling of an antigen-targeting detection probe with a secondary, catalytically active nanoparticle by utilizing secondary antibody interactions. Here, we show that signal enhancement is achieved through two functional mechanisms: network formation, facilitated by the secondary nanoparticle increasing the relative concentration of nanoparticles immobilized at the test zone; and the inclusion of catalytically active nanoparticles, which catalyze the oxidation of a chromogenic substrate at the test zone. Through this approach, we yielded a 40-fold improvement in the limit of detection (LOD) using 40 nm gold nanoparticle detection probes in spiked pooled human saliva. Further, the signal enhancement platform can be utilized alongside a range of detection probes, including gold nanoparticles, commonly employed for use in LFIAs. This work concludes by showcasing that the signal enhancement mechanism is compatible for use with complex sample matrices, such as human saliva.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.